MarketBeat
08 Aug 2026, 05:04 UTC · 13w ago
Emergent Biosolutions Q2 Earnings Call Highlights
Impact · against what's priced in
Emergent Biosolutions faces a significant valuation headwind as competitive pricing and new approvals in the naloxone market force a downward revenue guidance revision and a $191 million impairment charge. While strong Q2 execution in government contracts provides a floor, it does not offset the structural deterioration of the NARCAN commercial franchise.
- EBS−0.50
No priced-in read yet
- In context
The company slashed full-year revenue guidance to $645–$675 million from $720–$760 million and took a $191 million impairment on NARCAN due to aggressive pricing and new competitors. These fundamental declines outweigh the Q2 beat and $40 million in planned cost savings.
